Literature DB >> 23147521

Clinical guideline: management of gastroparesis.

Michael Camilleri1, Henry P Parkman, Mehnaz A Shafi, Thomas L Abell, Lauren Gerson.   

Abstract

This guideline presents recommendations for the evaluation and management of patients with gastroparesis. Gastroparesis is identified in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. Symptoms from gastroparesis include nausea, vomiting, early satiety, postprandial fullness, bloating, and upper abdominal pain. Management of gastroparesis should include assessment and correction of nutritional state, relief of symptoms, improvement of gastric emptying and, in diabetics, glycemic control. Patient nutritional state should be managed by oral dietary modifications. If oral intake is not adequate, then enteral nutrition via jejunostomy tube needs to be considered. Parenteral nutrition is rarely required when hydration and nutritional state cannot be maintained. Medical treatment entails use of prokinetic and antiemetic therapies. Current approved treatment options, including metoclopramide and gastric electrical stimulation (GES, approved on a humanitarian device exemption), do not adequately address clinical need. Antiemetics have not been specifically tested in gastroparesis, but they may relieve nausea and vomiting. Other medications aimed at symptom relief include unapproved medications or off-label indications, and include domperidone, erythromycin (primarily over a short term), and centrally acting antidepressants used as symptom modulators. GES may relieve symptoms, including weekly vomiting frequency, and the need for nutritional supplementation, based on open-label studies. Second-line approaches include venting gastrostomy or feeding jejunostomy; intrapyloric botulinum toxin injection was not effective in randomized controlled trials. Most of these treatments are based on open-label treatment trials and small numbers. Partial gastrectomy and pyloroplasty should be used rarely, only in carefully selected patients. Attention should be given to the development of new effective therapies for symptomatic control.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147521      PMCID: PMC3722580          DOI: 10.1038/ajg.2012.373

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  163 in total

1.  Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine.

Authors:  B D Maes; J Vanwalleghem; D Kuypers; Y Ghoos; P J Rutgeerts; Y F Vanrenterghem
Journal:  Transplantation       Date:  1999-11-27       Impact factor: 4.939

2.  Gastrointestinal tract symptoms among persons with diabetes mellitus in the community.

Authors:  D Maleki; G R Locke; M Camilleri; A R Zinsmeister; B P Yawn; C Leibson; L J Melton
Journal:  Arch Intern Med       Date:  2000-10-09

3.  Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.

Authors:  P J Lustman; K E Freedland; L S Griffith; R E Clouse
Journal:  Diabetes Care       Date:  2000-05       Impact factor: 19.112

4.  Gastric emptying in Type II (non-insulin-dependent) diabetes mellitus before and after therapy readjustment: no influence of actual blood glucose concentration.

Authors:  A Holzäpfel; A Festa; G Stacher-Janotta; H Bergmann; N Shnawa; W Brannath; G Schernthaner; G Stacher
Journal:  Diabetologia       Date:  1999-12       Impact factor: 10.122

Review 5.  Pathophysiology and treatment of functional dyspepsia.

Authors:  Jan Tack; Raf Bisschops; Giovanni Sarnelli
Journal:  Gastroenterology       Date:  2004-10       Impact factor: 22.682

6.  Subcutaneous metoclopramide in the treatment of symptomatic gastroparesis: clinical efficacy and pharmacokinetics.

Authors:  R W McCallum; G Valenzuela; S Polepalle; D Spyker
Journal:  J Pharmacol Exp Ther       Date:  1991-07-01       Impact factor: 4.030

7.  Gastroparesis after combined heart and lung transplantation.

Authors:  Sudeep S Sodhi; Jin-Ping Guo; Alan H Maurer; Gerald O'Brien; Radhika Srinivasan; Henry P Parkman
Journal:  J Clin Gastroenterol       Date:  2002-01       Impact factor: 3.062

8.  Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life.

Authors:  N J Talley; L Young; P Bytzer; J Hammer; M Leemon; M Jones; M Horowitz
Journal:  Am J Gastroenterol       Date:  2001-01       Impact factor: 10.864

9.  Idiopathic gastroparesis is associated with a multiplicity of severe dietary deficiencies.

Authors:  C P Ogorek; L Davidson; R S Fisher; B Krevsky
Journal:  Am J Gastroenterol       Date:  1991-04       Impact factor: 10.864

10.  The treatment of diabetic gastroparesis with botulinum toxin injection of the pylorus.

Authors:  Brian E Lacy; Michael D Crowell; Ann Schettler-Duncan; Carole Mathis; Pankaj J Pasricha
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

View more
  248 in total

1.  Clinical utility of wireless motility capsule in patients with suspected multiregional gastrointestinal dysmotility.

Authors:  Zubin Arora; Jose Mari Parungao; Rocio Lopez; Cynthia Heinlein; Janice Santisi; Sigurbjorn Birgisson
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

2.  [Gastroparesis: Critical consideration of therapeutic management].

Authors:  M Tiller; W Schepp; F Gundling
Journal:  Internist (Berl)       Date:  2015-09       Impact factor: 0.743

3.  The American Journal of Gastroenterology in 2016: Where Have We Been? Where Are We Going?

Authors:  Brian E Lacy; Brennan Spiegel
Journal:  Am J Gastroenterol       Date:  2016-01-12       Impact factor: 10.864

4.  Pathophysiology of Gastroparesis Syndromes Includes Anatomic and Physiologic Abnormalities.

Authors:  Thomas L Abell; Archana Kedar; Abigail Stocker; Karen Beatty; Lindsay McElmurray; Michael Hughes; Hani Rashed; William Kennedy; Gwen Wendelschafer-Crabb; Xiu Yang; Mostafa Fraig; Leila Gobejishvili; Endashaw Omer; Ed Miller; Michael Griswold; Christina Pinkston
Journal:  Dig Dis Sci       Date:  2020-04-23       Impact factor: 3.199

Review 5.  ACG and CAG Clinical Guideline: Management of Dyspepsia.

Authors:  Paul Moayyedi; Brian E Lacy; Christopher N Andrews; Robert A Enns; Colin W Howden; Nimish Vakil
Journal:  Am J Gastroenterol       Date:  2017-06-20       Impact factor: 10.864

Review 6.  Botulinum Toxin Injection for Treatment of Gastroparesis.

Authors:  Trisha S Pasricha; Pankaj J Pasricha
Journal:  Gastrointest Endosc Clin N Am       Date:  2018-09-28

7.  Fluoroscopy-guided gastric peroral endoscopic pyloromyotomy (G-POEM): a more reliable and efficient method for treatment of refractory gastroparesis.

Authors:  H B Xue; H Z Fan; X M Meng; S Cristofaro; P Mekaroonkamol; S Dacha; L Y Li; X L Fu; S H Zhan; Q Cai
Journal:  Surg Endosc       Date:  2017-04-13       Impact factor: 4.584

Review 8.  Gastroparesis: Medical and Therapeutic Advances.

Authors:  Christopher M Navas; Nihal K Patel; Brian E Lacy
Journal:  Dig Dis Sci       Date:  2017-07-18       Impact factor: 3.199

9.  Effect of neostigmine on gastroduodenal motility in patients with suspected gastrointestinal motility disorders.

Authors:  G Parthasarathy; K Ravi; M Camilleri; C Andrews; L A Szarka; P A Low; A R Zinsmeister; A E Bharucha
Journal:  Neurogastroenterol Motil       Date:  2015-09-20       Impact factor: 3.598

10.  Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis.

Authors:  Timothy Kaniecki; Tsion Abdi; Zsuzsanna H McMahan
Journal:  Med Res Arch       Date:  2020-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.